Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Intravenous (IV) Ibuprofen Market Growth in 2025?

The market size for intravenous (IV) ibuprofen has experienced rapid expansion in recent years. The value of this market will increase from $8.35 billion in 2024 to $9.4 billion in 2025 with a compound annual growth rate (CAGR) of 12.5%. The historic rise can be attributed to various factors such as the increasing occurrence of chronic illnesses, the rise in surgical procedures, the growing focus on reducing opioid usage, the increase in per capita income and the growth of medical tourism.

What Is the Forecast for the Intravenous (IV) Ibuprofen Market Size Through 2029?

Over the next several years, the market for intravenous (IV) ibuprofen is projected to expand rapidly, reaching a valuation of $14.86 billion in 2029 with a compound annual growth rate (CAGR) of 12.1%. The surge during the predicted period is due to several factors such as enhanced healthcare investments, growth in the number of pediatric patients, increased instances of pain and fever, a swelling elderly population, and the escalating acceptance of advanced pharmaceutical procedures. The forecast period is also anticipated to be marked by cutting-edge therapeutic solutions, single-dose formulas, strides in personalized medicine, incorporation into multi-modal pain control protocols, and advancements in combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23429&type=smp

What are the Key Market Players in Intravenous (IV) Ibuprofen Market and How They’re Evolving?

Major companies operating in the intravenous (IV) ibuprofen market are Pfizer Inc., Sanofi S.A., Novartis AG, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Baxter International, Mylan N.V., Sandoz Group AG, Grifols S.A., Dr. Reddy’s Laboratories, Hikma Pharmaceuticals plc, CSL Limited, Eurolife Healthcare Pvt. Ltd., B. Braun Holding GmbH & Co. KG, AFT Pharmaceuticals Ltd, Cumberland Pharmaceuticals Inc., Delex Pharma International Inc., Recordati Rare Diseases Inc., Xgen Pharmaceuticals Djb Inc., Wellona Pharma, Hyloris Pharmaceuticals SA

What Are the Primary Growth Drivers in the Intravenous (IV) Ibuprofen Market?

The increasing number of pain disorders is anticipated to drive the expansion of the intravenous ibuprofen market. Pain disorders are medical situations marked by ongoing or prolonged discomfort that impacts regular life functions, typically triggered by nerve, musculoskeletal, or inflammatory problems. The increase in pain disorders can be attributed to the aging population, as older individuals are more prone to chronic illnesses such as arthritis, osteoarthritis, and nerve pain, necessitating effective pain mitigation. Intravenous ibuprofen aids in pain control by offering expedited relief, making it perfect for severe and post-surgery pain. It decreases inflammation and increases patient comfort, enhancing the effectiveness of treatments in healthcare settings. For example, as per the Office for Health Improvement and Disparities, a UK government department, the proportion of people aged 16 and over declaring a prolonged musculoskeletal condition increased to 18.4% in 2023, up from 17.6% in 2022. Consequently, the growing number of pain disorders is fuelling the intravenous ibuprofen market’s expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23429&type=smp

What Are the Leading Segments in the Global Intravenous (IV) Ibuprofen Industry?

The intravenous (IV) ibuprofen market covered in this report is segmented –

1) By Product Type: Conventional Intravenous (IV) Ibuprofen, High-Concentration Intravenous (IV) Ibuprofen

2) By Strength: 100 Milligrams (mg), 200 Milligrams (mg), 400 Milligrams (mg), 800 Milligrams (mg)

3) By Age Group: Pediatrics, Adults

4) By Application: Pain, Fever, Inflammation, Other Applications

5) By End-User: Hospitals, Ambulatory Surgical Centers, Clinics, Other End-Users

Subsegments:

1) By Conventional Intravenous (IV) Ibuprofen: Pediatric Intravenous (IV) Ibuprofen, Adult Intravenous (IV) Ibuprofen

2) By High-Concentration Intravenous (IV) Ibuprofen: Single-Dose Vial, Multi-Dose Vial

What Are the Key Market Trends in the Intravenous (IV) Ibuprofen Industry?

Leading firms in the intravenous ibuprofen market are prioritizing the development of innovative drug formulas, such as opioid-free analgesics. These are designed to improve pain control whilst simultaneously decreasing reliance on opioids. An opioid-free analgesic is a medication that provides pain relief but does not include opioids, thereby eliminating the risk of addiction and opioid-related side effects. As an example, in February 2024, Hikma Pharmaceuticals plc, a pharmaceutical company located in the UK, received approval to launch COMBOGESIC IV ( acetaminophen and ibuprofen) injection in the United States, after obtaining FDA approval in October 2023. This intravenous analgesic that is free from opioids, is prescribed for mild to moderate pain relief and to supplement moderate to severe pain control. Through the combination of two active ingredients with different functions, COMBOGESIC IV offers a new, non-opioid pain management choice for healthcare professionals.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-iv-ibuprofen-global-market-report

What Is the Regional Outlook for the Intravenous (IV) Ibuprofen Market?

North America was the largest region in the intravenous (IV) ibuprofen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous (IV) ibuprofen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23429

This Report Delivers Insight On:

1. How big is the intravenous (iv) ibuprofen market, and how is it changing globally?

2. Who are the major companies in the intravenous (iv) ibuprofen market, and how are they performing?

3. What are the key opportunities and risks in the intravenous (iv) ibuprofen market right now?

4. Which products or customer segments are growing the most in the intravenous (iv) ibuprofen market?

5. What factors are helping or slowing down the growth of the intravenous (iv) ibuprofen market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model